UK Markets closed

Valneva SE American Depositary Shares (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.55+0.34 (+1.27%)
At close: 1:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close27.20
Open27.88
Bid24.16 x 900
Ask34.95 x 800
Day's range27.29 - 27.81
52-week range24.16 - 31.33
Volume1,560
Avg. volume27,307
Market capN/A
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

    Saint-Herblain (France) and New York, NY, July 19, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. (NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both ad

  • Globe Newswire

    Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate

    This new U.S. Milestone Follows FDA Fast Track and EMA PRIME Designations Saint Herblain (France), July 7, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration (FDA).

  • Globe Newswire

    Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

    Saint-Herblain (France), July 6, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations. Vincent Dequenne, engineer by training, has an extensive track record in the pharmaceutical industry with ov